文献速递产科母胎医学

炎症性肠病妊娠期生物制剂暴露与母婴结局

Exposure to biologic therapy and associated maternal and neonatal outcomes in pregnancies complicated by inflammatory bowel disease.
PubMed 文献 · Am J Obstet Gynecol MFM · 2021-10-22

这项回顾性队列研究纳入2012至2019年在本院分娩的322例炎症性肠病孕妇,其中112例(34%)孕期使用生物制剂。生物制剂组母亲感染性结局(22% vs 7%,P=.0003)和高血压性结局(19% vs 8%,P=.003)发生率显著更高,多变量回归后仍显著;新生儿不良结局两组无差异。

要点

  • 孕期使用生物制剂与母亲感染和高血压性结局风险升高相关。
  • 单用抗TNF治疗者感染(24% vs 6%)和高血压(22% vs 6%)风险亦升高。
  • 新生儿不良结局在生物制剂组与非暴露组间无差异。

核心结论

  • 产前使用生物制剂尤其是抗TNFα治疗与母亲感染性和高血压性结局风险增加相关。
  • 该风险可能与基础疾病活动度有关,需与患者讨论时权衡生物制剂对疾病控制的获益。

研究设计与样本

  • 回顾性队列研究,纳入2012至2019年在本院分娩的炎症性肠病孕妇322例。
  • 根据孕期生物制剂暴露分组,比较母亲和新生儿结局,并对复合结局进行多变量逻辑回归分析。

主要发现

  • 生物制剂组母亲感染性结局发生率为22%,非暴露组为7%(P=.0003)。
  • 生物制剂组母亲高血压性结局发生率为19%,非暴露组为8%(P=.003)。
  • 单用抗TNF治疗者感染性结局为24% vs 未用药者6%(P=.002),高血压性结局为22% vs 6%(P=.004)。
  • 两组新生儿不良结局无差异。

关键数值与推荐

  • 生物制剂组中位BMI为22.4,非生物制剂组为24.0(P=.04)。
  • 生物制剂组经产妇比例为41%,非生物制剂组为59%(P=.003)。
  • 生物制剂组有既往炎症性肠病手术史的克罗恩病患者比例为33%,非生物制剂组为20%(P=.01)。

临床怎么用

  • 对炎症性肠病孕妇使用生物制剂前应告知母亲感染和高血压性结局风险可能增加。
  • 同时应强调生物制剂对控制疾病活动度、避免疾病恶化相关不良妊娠结局的获益。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is growing evidence that biologic therapy is safe in pregnancies complicated by inflammatory bowel disease and that its use outweighs the risk of worsening disease activity, which is associated with adverse pregnancy outcomes. To our knowledge, there are limited data regarding the use of biologic therapy and the associated maternal adverse effects such as the risk of hypertensive outcomes, postoperative complications, and infectious risk. OBJECTIVE: Our objective was to evaluate a variety of obstetrical complications including maternal infectious outcomes, hypertensive outcomes, other adverse maternal outcomes including postoperative complications, venous thromboembolism, and postpartum hemorrhage; we also evaluated the neonatal outcomes associated with biologic use in pregnancies affected by inflammatory bowel disease. STUDY DESIGN: This was a retrospective cohort study including patients with inflammatory bowel disease who were pregnant and delivered at our institution. The maternal demographics and the incidence of maternal and neonatal outcomes were compared among groups on the basis of biologic exposure using the chi-square or Fisher exact test for categorical variables and the t test or Mann-Whitney test for continuous variables. Multivariable logistic regression analysis was performed on composite outcomes adjusting for age, disease activity, maternal obesity, history of cesarean delivery, and history of corticosteroid use in pregnancy. The statistical significance was defined as P<.05. RESULTS: A total of 322 patients who were pregnant, had inflammatory bowel disease, and delivered at our institution from 2012 to 2019, were included for analysis. Of these, 112 (34%) were on biologics during pregnancy. The patients in the biologic group had significantly lower body mass indices than the patients in the nonbiologic group (median body mass index, 22.4 vs 24.0, respectively; P=.04), and they were less likely to be multiparous (41% vs 59%, respectively; P=.003). In addition, more patients in the biologic group were likely to have Crohn disease with previous inflammatory bowel disease surgery (33% vs 20%, respectively; P=.01); otherwise, the 2 groups had similar baseline characteristics. Maternal infectious and hypertensive outcomes occurred significantly more frequently in the biologic group than the nonexposed group (22% vs 7%; P=.0003 and 19% vs 8%; P=.003, respectively). This remained statistically significant in multivariable logistic regression models. Specifically, maternal infectious and hypertensive outcomes occurred significantly more frequently in the patients on a single-agent antitumor necrosis factor treatment than the patients on no inflammatory bowel disease medication (24% vs 6%; P=.002; 22% vs 6%; P=.004), which remained statistically significant in multivariable logistic regression models. There was no difference in the neonatal adverse outcomes between the 2 groups. CONCLUSION: Our data suggest an association between antepartum biologic use- specifically antitumor necrosis factor alpha therapy-and an increased risk of maternal infectious and hypertensive outcomes. This increased risk may be related to underlying disease activity and the same should be incorporated into a discussion with the patient. However, the discussion must be balanced with the important benefit of optimal disease control associated with biologic use in patients being treated for IBD.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Rekawek P, Johnson S, Bigelow CA, et al. Exposure to biologic therapy and associated maternal and neonatal outcomes in pregnancies complicated by inflammatory bowel disease. Am J Obstet Gynecol MFM. 2021. PMID: 34688951. doi:10.1016/j.ajogmf.2021.100518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。